TY - JOUR
T1 - Contemporary advances in antibody-mediated encephalitis
T2 - anti-LGI1 and anti-Caspr2 antibody (Ab)-mediated encephalitides
AU - Seery, Nabil
AU - Butzkueven, Helmut
AU - O'Brien, Terence J.
AU - Monif, Mastura
N1 - Funding Information:
NS has received conference fee sponsorship from Roche. TO has received support from the National Health and Medical Research Council , The National Institute of Neurological Disorders and Stroke and Monash University . He has been supported by research grants and consultancies to his institution from Eisai, UCB Pharma, Praxis Precision Medicines, BioGen and Supernus. MM has served on advisory board for Merck, has received speaker honoraria from Merch and Biogen. Her institution receives funding from Merc, Australian National Health Medical Research Council, Brain Foundation, Charles and Sylvia Viertel Foundation, and MS Research Australia. HB’s institution receives funding from Biogen, Roche, Merck and Novartis for speaker engagements, study steering and advisory committee service. He is on the editorial board of Multiple Sclerosis and Related Disorders and the Steering committee of the Brain Health Initiative (Oxford Health Policy Forum).
Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/5
Y1 - 2022/5
N2 - Encephalitides with antibodies directed against leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated protein-like 2 (Caspr2) represent two increasingly well characterised forms of autoimmune encephalitis. Both share overlapping and distinct clinical features, are mediated by autoantibodies directed against differing proteins complexed with voltage-gated potassium channels, with unique genetic predisposition identified to date. Herein we summarise disease mechanisms, clinical features, treatment considerations, prognostic factors and clinical outcomes regarding these disorders.
AB - Encephalitides with antibodies directed against leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated protein-like 2 (Caspr2) represent two increasingly well characterised forms of autoimmune encephalitis. Both share overlapping and distinct clinical features, are mediated by autoantibodies directed against differing proteins complexed with voltage-gated potassium channels, with unique genetic predisposition identified to date. Herein we summarise disease mechanisms, clinical features, treatment considerations, prognostic factors and clinical outcomes regarding these disorders.
KW - Anti-contactin-associated protein-like 2 (Caspr2) encephalitis
KW - Anti-leucine-rich glioma-inactivated-1 (LGI1) encephalitis
KW - LGI1-, Caspr2-encephalitis pathogenesis, clinical features, management
KW - LGI1-, Caspr2-encephalitis prognostic features, outcomes
UR - https://www.scopus.com/pages/publications/85125708657
U2 - 10.1016/j.autrev.2022.103074
DO - 10.1016/j.autrev.2022.103074
M3 - Review Article
C2 - 35247644
AN - SCOPUS:85125708657
SN - 1568-9972
VL - 21
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
IS - 5
M1 - 103074
ER -